Agenus Company Profile (NASDAQ:AGEN)

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AGEN
  • CUSIP: 00847G70
  • Web: www.agenusbio.com
Capitalization:
  • Market Cap: $337 million
  • Outstanding Shares: 99,118,000
Average Prices:
  • 50 Day Moving Avg: $3.58
  • 200 Day Moving Avg: $4.06
  • 52 Week Range: $3.20 - $7.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.28
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $43.57 million
  • Price / Sales: 7.73
  • Book Value: $0.09 per share
  • Price / Book: 37.78
Profitability:
  • EBIDTA: ($85,440,000.00)
  • Net Margins: -472.80%
  • Return on Equity: -359.98%
  • Return on Assets: -47.88%
Debt:
  • Debt-to-Equity Ratio: -6.00%
  • Current Ratio: 3.14%
  • Quick Ratio: 3.14%
Misc:
  • Average Volume: 1.11 million shs.
  • Beta: 2.51
  • Short Ratio: 8.52
 

Frequently Asked Questions for Agenus (NASDAQ:AGEN)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The firm earned $26.96 million during the quarter, compared to analysts' expectations of $5.22 million. Agenus had a negative net margin of 472.80% and a negative return on equity of 359.98%. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

4 equities research analysts have issued 1 year target prices for Agenus' stock. Their forecasts range from $5.00 to $7.00. On average, they anticipate Agenus' share price to reach $6.33 in the next twelve months. View Analyst Ratings for Agenus.

What are analysts saying about Agenus stock?

Here are some recent quotes from research analysts about Agenus stock:

  • 1. According to Zacks Investment Research, "Agenus focuses on the development of checkpoint modulators, vaccines and adjuvants for cancer treatments. With no approved product in its portfolio, the company is heavily dependent on its collaborators for top-line growth. In addition, the company is dependent on its partners for pipeline development. Moreover, Agenus has few candidates in mid-stage of development including Prophage vaccine and several QS-21 Stimulon-containing vaccine candidates. Any unfavorable outcome from the studies may affect the company’s shares adversely. However, the company received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. Moreover, the company’s collaboration agreements provide a steady source of funds. Agenus’ shares have outperformed the Medical/Biomedical Genetics industry." (12/27/2016)
  • 2. Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)

Who are some of Agenus' key competitors?

Who owns Agenus stock?

Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Oracle Investment Management Inc. (1.72%), FMR LLC (0.00%), Goldman Sachs Group Inc. (0.68%), Bank of New York Mellon Corp (0.57%) and Geode Capital Management LLC (0.00%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

Who sold Agenus stock? Who is selling Agenus stock?

Agenus' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, FMR LLC, Alliancebernstein L.P., TIAA CREF Investment Management LLC, California Public Employees Retirement System and Nationwide Fund Advisors. View Insider Buying and Selling for Agenus.

Who bought Agenus stock? Who is buying Agenus stock?

Agenus' stock was acquired by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Goldman Sachs Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Bank of New York Mellon Corp, Chicago Equity Partners LLC and Highbridge Capital Management LLC. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agenus stock cost?

One share of Agenus stock can currently be purchased for approximately $3.40.

Analyst Ratings

Consensus Ratings for Agenus (NASDAQ:AGEN) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.33 (86.27% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/23/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $15.00N/AView Rating Details
12/31/2015Oppenheimer Holdings Inc.Reiterated RatingPositive -> Outperform$14.00N/AView Rating Details
9/10/2015William BlairReiterated RatingBuyN/AView Rating Details
7/27/2015MLV & Co.Reiterated RatingBuy$9.00 -> $11.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Agenus (NASDAQ:AGEN)
Earnings by Quarter for Agenus (NASDAQ:AGEN)
Earnings History by Quarter for Agenus (NASDAQ:AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agenus (NASDAQ:AGEN)
2017 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.33)($0.24)($0.29)
Q2 20172($0.30)($0.24)($0.27)
Q3 20172($0.31)($0.25)($0.28)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 45.40%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.00View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.00View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.00View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
Source:
DateHeadline
prnewswire.com logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO ... - PR Newswire (press release)
www.prnewswire.com - May 22 at 3:24 PM
finance.yahoo.com logoAgenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting
finance.yahoo.com - May 22 at 3:24 PM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:24 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Agenus, Athersys ... - PR Newswire (press release)
www.prnewswire.com - May 19 at 3:24 PM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:48 PM
americanbankingnews.com logo$5.19 Million in Sales Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - May 10 at 9:16 AM
finance.yahoo.com logoAgenus, Inc. :AGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:23 PM
americanbankingnews.com logo Brokerages Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 8 at 10:27 PM
finance.yahoo.com logoAgenus, Inc. – Value Analysis (NASDAQ:AGEN) : May 8, 2017
finance.yahoo.com - May 8 at 8:47 PM
baystreet.ca logoAgenus Stock Bounces on Q1 Report, Update
www.baystreet.ca - May 5 at 8:25 PM
americanbankingnews.com logoAgenus Inc (AGEN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM
nasdaq.com logoAgenus (AGEN) Reports Narrower-than-Expected Loss in Q1 - Nasdaq
www.nasdaq.com - May 5 at 3:24 PM
finance.yahoo.com logoAgenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : May 5, 2017
finance.yahoo.com - May 5 at 3:24 PM
finance.yahoo.com logoAgenus (AGEN) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 5 at 3:24 PM
reuters.com logoBRIEF-Agenus Q1 loss per share $0.18
www.reuters.com - May 4 at 8:26 PM
fool.com logoHere's Why Agenus Inc. Stock Is Climbing Today
www.fool.com - May 4 at 8:26 PM
finance.yahoo.com logoInvestor Network: Agenus Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 8:26 PM
finance.yahoo.com logoAgenus Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 8:26 PM
finance.yahoo.com logoHere's Why Agenus Inc. Stock Is Climbing Today
finance.yahoo.com - May 4 at 8:26 PM
prnewswire.com logoAgenus Reports First Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:24 PM
finance.yahoo.com logoAgenus (AGEN) Reports Narrower-than-Expected Q1 Loss
finance.yahoo.com - May 4 at 3:24 PM
marketbeat.com logoAgenus reports 1Q loss
marketbeat.com - May 4 at 9:12 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Extremely Likely to Affect Agenus (AGEN) Share Price
www.americanbankingnews.com - May 3 at 10:15 AM
americanbankingnews.com logoAgenus Inc (AGEN) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 7:28 AM
streetinsider.com logoArray Biopharma (ARRY) Appoints Shalini Sharp to Board
www.streetinsider.com - April 27 at 8:43 PM
bizjournals.com logoShalini Sharp Joins Array BioPharma Board of Directors
www.bizjournals.com - April 27 at 3:43 PM
finance.yahoo.com logoAgenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow
finance.yahoo.com - April 27 at 3:43 PM
americanbankingnews.com logoAgenus (AGEN) Receiving Somewhat Negative News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 1:50 PM
nasdaq.com logoWhat's in Store for Agenus (AGEN) this Earnings Season?
www.nasdaq.com - April 24 at 3:26 PM
finance.yahoo.com logoFirst malaria vaccine to be tested in Africa, with boost from Lexington's Agenus
finance.yahoo.com - April 24 at 3:26 PM
americanbankingnews.com logoAgenus Inc to Post FY2019 Earnings of ($1.34) Per Share, William Blair Forecasts (AGEN)
www.americanbankingnews.com - April 24 at 12:27 PM
finance.yahoo.com logoWhat's in Store for Agenus (AGEN) this Earnings Season? - Yahoo Finance
finance.yahoo.com - April 24 at 10:58 AM
finance.yahoo.com logoWhat's in Store for Agenus (AGEN) this Earnings Season?
finance.yahoo.com - April 24 at 10:58 AM
americanbankingnews.com logoAgenus Inc (AGEN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 24 at 7:52 AM
americanbankingnews.com logoAgenus Inc (AGEN) Rating Reiterated by Maxim Group
www.americanbankingnews.com - April 23 at 10:26 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Impact Agenus (AGEN) Stock Price
www.americanbankingnews.com - April 23 at 7:46 AM
prnewswire.com logoPhase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins - PR Newswire (press release)
www.prnewswire.com - April 21 at 3:22 PM
reuters.com logoBRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins
www.reuters.com - April 21 at 1:28 AM
streetinsider.com logoForm 8-K AGENUS INC For: Apr 20 - StreetInsider.com
www.streetinsider.com - April 20 at 3:25 PM
finance.yahoo.com logoPhase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
finance.yahoo.com - April 20 at 3:24 PM
americanbankingnews.com logoAgenus (AGEN) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 20 at 10:47 AM
americanbankingnews.com logo Analysts Anticipate Agenus Inc (AGEN) Will Announce Quarterly Sales of $5.06 Million
www.americanbankingnews.com - April 19 at 9:25 AM
americanbankingnews.com logoAgenus Inc (AGEN) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 18 at 12:09 AM
americanbankingnews.com logoAgenus (AGEN) Receives Coverage Optimism Score of 0.13
www.americanbankingnews.com - April 15 at 8:53 AM
americanbankingnews.com logoInsider Buying: Agenus Inc (AGEN) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - April 13 at 8:02 AM
nasdaq.com logoWhy Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - April 11 at 8:23 AM
finance.yahoo.com logoWhy Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report?
finance.yahoo.com - April 11 at 8:23 AM
finance.yahoo.com logoETFs with exposure to Agenus, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 3:23 PM
americanbankingnews.com logoAgenus Inc (AGEN) Short Interest Update
www.americanbankingnews.com - April 8 at 7:26 AM
reuters.com logoBRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax
www.reuters.com - April 7 at 3:23 PM

Social

Agenus (AGEN) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff